Tradestie Institutional Equity Comparison Engine · Market Close May 04, 2026

ABPWW vs EKSO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EKSO Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 8–0 Matrix Metrics)

EKSO Overall Winner 6-Pillar Tally: ABPWW 0 – 4 EKSO (2 Tie) Matrix Metrics: ABPWW 0 – 8 EKSO

As of May 04, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Abpro Holdings, Inc. Warrant (ABPWW) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABPWW carries a Unified Composite Score of 45.0/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABPWW vs EKSO
ABPWW NASDAQ
Abpro Holdings, Inc. Warrant
Institutional Equity
$0.01
+0.0% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -1.56β · 265% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
EKSO NASDAQ Head-to-Head Winner
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65

6-Pillar Scorecard Institutional Category Breakdown (ABPWW 0 – 4 EKSO)

Columns: Metric · ABPWW · EKSO
1. Valuation Multiples EKSO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 3.3x
2. Growth & Scale EKSO
Revenue Growth (YoY) N/A -38.3%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $13M
Market Cap N/A $42.0M
3. Profitability & Quality EKSO
Gross Margin N/A 53.5%
Operating Margin N/A -119.7%
Net Profit Margin N/A -91.4%
Return on Equity (ROE) N/A -107.6%
4. Balance Sheet & Cash Flow EKSO
Cash Generation (TTM) N/A -$11M EBITDA
Cash Flow Margin N/A -86.0% EBITDA Mgn
Net Cash / Leverage N/A ROE $2.54 Book/Sh · -107.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABPWW (0) vs EKSO (8)
Institutional Metric ABPWW EKSO Criterion Row Edge
Market Capitalization
Scale
N/A $42.0M Larger Scale EKSO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -38.3% Higher Growth EKSO
Operating Margin (TTM)
Profitability
N/A -119.7% Higher Margin EKSO
Net Profit Margin
Profitability
N/A -91.4% Higher Margin EKSO
Return on Equity (ROE)
Capital Efficiency
N/A -107.6% Higher ROE EKSO
52-Week Range Position
Momentum
0% ($0–$0) 87% ($0–$14) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
-1.56β · 265% Vol 2.16β · 76% Vol Lower Realized Risk EKSO
Unified Institutional Score
Composite Signal
45.0 / 100 (HOLD) 58.1 / 100 (HOLD) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
N/A $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 53.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EKSO +72.97 pp
ABPWW: -17.86% · EKSO: +55.11%
3M Horizon EKSO +182.37 pp
ABPWW: -58.33% · EKSO: +124.04%
6M Horizon EKSO +211.66 pp
ABPWW: -32.75% · EKSO: +178.91%
1Y Horizon EKSO +109.28 pp
ABPWW: -39.79% · EKSO: +69.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABPWW vs EKSO. Trailing 12-month operating profitability (ABPWW N/A vs EKSO -119.7%) and valuation multiples (ABPWW N/M vs EKSO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABPWW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABPWW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABPWW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABPWW Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABPWW vs EKSO Key Questions & Quantitative Answers

As of May 04, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Abpro Holdings, Inc. Warrant (ABPWW) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABPWW carries a Unified Composite Score of 45.0/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin). Technically, ABPWW sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure) and EKSO sits in a Markup phase (RSI 60.4, UNCLASSIFIED options structure).

EKSO leads the Growth & Scale pillar: ABPWW posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with EKSO at -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin). On trailing 12-month operating scale, ABPWW generates N/A in USD-normalized revenue versus $13M for EKSO. In operating R&D and SG&A reinvestment, ABPWW deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EKSO.

EKSO screens cheaper on headline valuation multiples. ABPWW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABPWW (N/A ROE) versus EKSO (-107.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ABPWW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.56β · 265% Vol realized risk). By comparison, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of May 04, 2026. For educational research only; not investment advice.